BioSpace News Archive

Award-winning healthcare design innovation firm named as a winner in Health category and honorable mention in General Excellence category amongst 4,300 applicants

Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11-13, 2019.

Proliant Biologicals, LLC (Proliant), an LGI company (Lauridsen Group Inc.), today announced that it has acquired Boval BioSolutions from Lifecycle Biotechnologies of Fort Worth, TX.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that an abstract with data from 15 patient cases where the Company’s SkinTE™ product was used to treat a variety of wounds was accepted for a podium presentation at the American Society of Plastic Surgeons’ scientific meeting, Plastic Surgery The Meeting,

The registered nurses at Steward Nashoba Valley Medical Center (NVMC) in Ayer, who are represented by the Massachusetts Nurses Association (MNA), have filed unfair labor practice charges at the U.S. National Labor Relations Board (NLRB) against the Dallas-based for profit health care corporation after it issued a threat to close the hospital unless the nurses stopped attempting to bargain and accept Steward’s “final” offer.

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company’s lead antifungal candidate, fosmanogepix (APX001

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019, the Company was formally notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the applicable stockholders’ equity requirement.

CenExel Clinical Research, Inc., (“CenExel” or the “Company”) announced that Anaheim Clinical Trials (ACT), an adult and pediatric Phase I through Phase IV clinical research Center of Excellence, recently underwent three separate routine national agency audits within 45 days.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal third quarter ended July 31, 2019.

A portion of proceeds from gown rentals will be donated to the National Pediatric Cancer Foundation